Please provide your email address to receive an email when new articles are posted on . Sunovion recently announced positive phase 3 study findings for Latuda for bipolar I disorder depression in ...

Latuda, a new bipolar anti-depression brand from Sunovion, has joined the DTC fray with an integrated campaign targeted at women betweeen 25 and 49. This is a very complicated disease to ...

Mark Iwicki’s top priority is driving the success of Latuda, an atypical antipsychotic for adults with schizophrenia. “It’s the most important product and business we have for the next couple of years ...

Sunovion Pharmaceuticals Inc. recently announced study results that indicated Latuda statistically significantly improved schizophrenia symptoms among adolescents. “These results show that Latuda may ...

Sunovion Pharmaceuticals Inc., a Marlborough based drug company now owned by Dainippon Sumitomo Pharma Co. Ltd. of Japan, said that it has received regulatory approval to market its Latuda drug for ...

Latuda's (lurasidone HCI; Sunovion) expanded indication has been approved for pediatric patients aged 10 to 17 years who have major depressive episodes associated with bipolar I disorder. The Food and ...

LATUDA (luradisone HCl) 20mg, 40mg, 80mg tablets by Sunovion Latuda (lurasidone HCl; Sunovion) is the first atypical antipsychotic indicated for the treatment of major depressive episodes associated ...

Sunovion Pharmaceuticals' new antipsychotic drug has hit drugstores, aiming to capture a share of the already crowded market. It's a branded drug in a class that now includes one leading ...

The Food and Drug Administration approved a new use for Sunovion Pharmaceuticals’ Latuda to treat schizophrenia in kids aged 13 to 17 years. The drug was first approved in 2010 as a treatment for ...

The FDA has given the green light to Dainippon Sumitomo Pharma's Latuda (lurasidone), an atypical antipsychotic. The drug is designed to work like other atypcals such as Zyprexa, Risperdal or Seroquel ...